Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics develops ficerafusp alfa, an investigational antibody therapy for solid tumors such as head and neck cancers. It last closed at $9.60 on Nov 17, down 1.54% on the day. The average 12-month price target from 6 analysts is $29.67 (+209.0% from the last close), with a high of $43.00 and a low of $8.00. Analyst consensus is Buy, based on the latest ratings from 6 firms (5 buy, 0 hold, 1 sell). In the past 30 days there were 2 dark pool prints totaling $1.1M, the largest $667K.
Key Stats
Last 12 monthsNot reported for this period.
From BCAX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 6 analysts who set a price target on BCAX in the past 90 days. The average target is $29.67, with a high of $43.00 and a low of $8.00, compared with the last close of $9.60.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 11 | HC Wainwright & Co. | Maintained | Buy | $36 |
| Nov 10 | Morgan Stanley | Target lowered | Buy | $39 → $30 |
| Nov 10 | Stifel | Maintained | Buy | $43 |
| Nov 10 | BTIG | Target lowered | Buy | $39 → $37 |
| Oct 30 | Goldman Sachs | Downgrade | Sell | $20 → $8 |
Technical Analysis
The stock is 19% below its 20 day and 70% below its 50 day average. It is 116% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 33), near oversold. The nearest support is the Pivot S1 at $9.34, and the nearest resistance the Pivot R1 at $9.85.
| RSI (14) | 32.61 | Weak, oversold below 30 | Neutral |
| MACD | -2.04 | Above its signal line | Bullish |
| Stochastic | 30.1 | Middle of its range | Neutral |
| ADX (14) | 48.4 | Strong downtrend | |
| Williams %R | -51.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -43.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +7.1% | Change over 10 sessions | Bullish |
| ATR (14) | $1.14 | Typical daily range, 11.8% of price |
| RSI (14) | 26.34 | Oversold below 30 | Oversold |
| MACD | -3.17 | Below its signal line | Bearish |
| Stochastic | 7.8 | Near the bottom of its range | Oversold |
| ADX (14) | 29.0 | Trending down | |
| Williams %R | -90.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -133.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −57.9% | Change over 10 sessions | Bearish |
| ATR (14) | $2.83 | Typical daily range, 29.4% of price |
What happened before
See how BCAX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in BCAX in the last 90 days.
Dark Pool
30DBCAX Institutional Ownership
Full report →- ▲95 buying vs 67 selling
- ▼Held by funds -0.8 pts
- ▼Funds holding -3
- ▲Superinvestors: 3 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 169 | 172 | −1.7% |
| In funds' top 10 | 5 | 9 | −44.4% |
| Held by funds | 104.3% | 105.1% | −0.8 pts |
| New / increased | 25 / 70 | 36 / 68 | −8.7% |
| Reduced / sold out | 40 / 27 | 38 / 11 | +36.7% |
| Put/call ratio | 0.19 | 1.00 | −81.1% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BCAX is in one of them and how their past BCAX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BCAX in an article yet. Here's the latest on the wider market.
About Bicara Therapeutics
Bicara Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that is developing treatments for solid tumors. Its main candidate, ficerafusp alfa, is an investigational antibody that pairs an antibody targeting the EGFR protein on tumor cells with a molecule that blocks TGF-β, a signaling protein that helps tumors resist treatment. The candidate is being tested mainly in head and neck squamous cell carcinoma, and the company does not yet sell a product. Its intended patients are people with solid tumors, starting with head and neck cancers.
- Headquarters
- Boston, MA


